Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP12 | P39900 | 3/20 | 0.45 |
| ▸ | MMP14 | P50281 | 3/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357653 | 0.90 | NAAA (0.53) | FOLH1ALBMMP2MMP9MMP8 | |
| SCHEMBL15783568 | 0.90 | CASP2 (0.56) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL14118084 | 0.90 | FOLH1 (0.46) | FOLH1ALBMMP2MMP9MMP8 | |
| SCHEMBL25358474 | 0.90 | FOLH1 (0.52) | FOLH1ALBGLP1RNOD1ALDH1A1 | |
| SCHEMBL25357657 | 0.90 | NAAA (0.53) | FOLH1ALBMMP2MMP9MMP8 | |
| SCHEMBL25358482 | 0.90 | FOLH1 (0.52) | FOLH1ALBGLP1RNOD1ALDH1A1 | |
| SCHEMBL14118103 | 0.90 | NOD1 (0.50) | FOLH1ALBMMP2MMP9MMP8 | |
| SCHEMBL31688586 | 0.89 | FOLH1 (0.51) | FOLH1ALBGLP1RNOD1 | |
| SCHEMBL13223744 | 0.89 | ALB (0.46) | FOLH1ALBMMP2MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL23834203 | 0.89 | CASP2 (0.54) | MMP2MMP9MMP8MMP12MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | FOLH1 2002/4885ALB 119/4885MMP2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.